Form 8-K Summary
Registrant and reporting period: The filing is by Anzu Special Acquisition Corp I, a Delaware special purpose acquisition company, dated December 6, 2021, with the report signed December 7, 2021. The request identifies Envoy Medical, Inc., but Envoy is not the registrant named in the filing.
Business Context and Transaction
Anzu entered into forward purchase agreements with institutional investors, including Arena Capital Advisors, LLC and Fir Tree Partners, in connection with a potential future business combination. No definitive business combination agreement had been entered into as of the filing date.
- Up to $80 million of unsecured convertible notes may be purchased immediately before the business combination closing. Conversion terms were not yet finalized.
- Up to 4 million forward purchase securities may be purchased at $10 per security, for aggregate proceeds of up to $40 million. Each security would include one share of Class A common stock and one-sixth of a warrant transferred by the sponsor.
- Each whole warrant would be exercisable for one Class A common share at $11.50 per share.
- If Anzu seeks additional private-placement equity financing for the business combination, the forward purchasers would receive a first offer to purchase up to $120 million of those securities on the same terms.
Financial Metrics and Liquidity
The filing does not report revenue, profit, cash flow, margins, debt balances, or current liquidity. The potential financing could provide up to $120 million in aggregate proceeds through convertible notes and forward purchase securities, but these amounts are not committed funding and may not be issued.
Material Changes Versus Prior Period
The material development is Anzu’s entry into the forward purchase agreements. The agreements establish a potential source of financing for a future business combination but do not constitute a completed financing, securities issuance, or business combination.
Outlook, Risks, and Unusual Items
- Each transaction remains subject to conditions, including approval by the applicable forward purchaser’s investment committee. Those committees have no obligation to approve or complete the investments.
- The terms of the convertible notes, including conversion terms, remained subject to negotiation.
- There is no assurance that the securities will be issued, that the stated proceeds will be received, or that Anzu will enter into or close a business combination.
- The securities are expected to be issued without registration under the Securities Act in reliance on Section 4(a)(2) and/or Regulation D.
- Forward purchasers will receive registration rights for the relevant shares, warrants, and shares underlying the convertible notes.
- The filing’s forward-looking statements are subject to risks described in Anzu’s final IPO prospectus filed March 3, 2021.
Investor Verification Points
- Confirm whether a definitive business combination agreement was subsequently signed and whether a transaction involving Envoy Medical was completed.
- Verify whether any convertible notes or forward purchase securities were ultimately issued, and the final terms, pricing, conversion features, and proceeds.
- Determine whether the forward purchasers’ investment committees approved the investments.
- Review subsequent filings for dilution, redemption activity, warrant terms, registration rights, and the use of proceeds.
- Confirm the registrant identity, because this filing is for Anzu Special Acquisition Corp I rather than Envoy Medical, Inc.